RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives

M. V. Madhubabu, ^a R. Shankar, ^a Satish.s.More, ^a Mandava V. Basaveswara Rao, ^b U. K. Syam ^s Kumar, ^a Ragunadh Akula ^a

A convenient and one-pot synthesis of tetracylic isoindolo [1,2-a]quinazoline derivatives via a Lewis Acid mediated sequential C-N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazoline motifs were synthesized in good yields.

15 Isoindoloquinazolinones symbolize as the core structure in numerous biologically active molecules. In addition, they are also important building blocks of potential drug molecules and natural products such as Camptothecin 1, Belotecan (CKD-602) 2, Batracylin 3, Tryptanthrin 4, Ophiuroidine 5, (-)-Vasicine 20 6, Luotonin 7a, 7b & 7c, and Auranthine 8 (Fig 1). Isoindolo quinazolinones have been reported with anti-cancer, anti-viral, anti-tubercular and anti-malarial activities. Recently Yang and co-workers reported that substituted quinazolines have novel potent and selective FLT3 inhibitory and anti-acute myeloid 25 leukaemia (AML) activities.

Because of varied biological properties of quinazolinone derivatives, it is necessary to develop efficient and convenient methods to prepare Isoindoloquinazolinone derivatives. Throughout the course of our literature survey we found minimum number of reports for the preparation of isoindoloquinazoline derivatives. Mitscher *et al.* have described intramolecular Aza-Wittig reaction using triethylamine, ¹⁰ Weaver *et al.* have reported oxidative radical cyclization for synthesis of quinazolines from quinazolin- ³⁵ 4(3H)-one. ¹¹

The development of simple methodology for the preparation of Isoindoloquinazolinone derivatives is always in demand. In the past, our group described numerous protocols for the preparation of quinazolinone based natural products and their derivatives. 12

forward synthesis of poly-substituted Isoindoloquinazolinones derivatives.

In this communication, we wish to report simple and straight

Fig. 1. Examples of natural products containing quinazolinone skeletons.

The synthetic strategy employed for the synthesis of (Z)-1260 benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline
derivatives is depicted in **Scheme 1.** The (Z)-12-benzylidene10, 12-dihydroisoindolo[1,2-b]quinazolines derivatives **11a**could be easily obtained by a reaction of (2aminophenyl)methanol **9a**¹³ with 2-(phenylethynyl)
65 benzonitrile **10a**. 14

$$N$$
 R^6
 $10a$
 $9a$

Scheme 1: Retrosynthesis of 11a.

†Electronic Supplementary Information (ESI) available: Experimental procedures, spectral data for all new compounds, copies of spectra. For ESI see DOI: 10.1039/b000000x/

^aTechnology Development Centre, Custom Pharmaceutical Services, Dr. Reddy's Laboratories Ltd, Hyderabad 500049, India

^bDepartment of Chemistry, Krishna university, Machilipatnam, Andhra 45 Pradesh, India.

E-mail:raghunadha@drreddys.com,

The compound 11 was characterized by ¹H NMR, ¹³C NMR, HRMS and IR. Substituted (*Z*)-12-benzylidene-10,12-dihydroisoindolo [1,2-b]quinazoline derivatives were prepared from (2-aminophenyl)methanol 9 with 2-(phenylethynyl) benzonitrile 10.

In an effort to develop an optimal conditions, various reaction parameters were studied for the preparation of 11 *via* condensation of 2-(phenylethynyl)benzonitrile 10 (1.0 eq) with (2-aminophenyl)methanol 9 (1.0 eq) and BF₃.Et₂O (3.0 eq). The acids have a strong effect on these reactions with respect to yield.

Table 1: Screening of various acids.

Entry	Lewis acid (eq/vol)	Yield (%) ^b	
1	BF ₃ ·Et ₂ O ^a (3.0eq)	62	
2	$BF_3.Et_2O^a(1.5\ eq)$	49	
3	$BF_3 \cdot Et_2O^a(2.0eq)$	61	
4	$BF_3 \cdot Et_2O^c$ (3.0eq)	49	
5	$BF_3 \cdot Et_2O^d(3.0eq)$	26	
6	BF ₃ ·2AcOOH (3.0eq)		
7	Acetic acid (5.0 eq)	8	
8	TFA (5.0 eq)	16	
9	$H_2SO_4(2.0eq)$	12	
10	AlCl ₃ (3.0eq)	22	
11	AlBr ₃ (3.0eq)	18	
12	$Hg(OAc)_2(3.0eq)$	Traces	
13	TiCl ₄ (3.0eq)	41	

^a48-50 % solution of reagent was used, ^bIsolated yields after column chromatography, ^c reaction at 45 °C, ^d reaction with Boron trifluoride acetic acid complex at 25 °C.

Reaction and conditions: (2-aminophenyl)methanol 9 (1.0 eq.) 2-

Reaction and conditions: (2-aminophenyl)methanol 9 (1.0 eq), 2-(phenylethynyl)benzonitrile 10 (1.0 eq) and BF₃.Et₂O (3.0 eq) at 70 °C.

Among all the screened acids, optimum yields were obtained when the reaction was performed in the presence of BF₃.Et₂O (3.0 eq) (Table 1). Solvents like DMSO, DMF, 1,4-Dioxane, THF, Acetonitrile and Toluene were screened in presence of BF₃.Et₂O. BF₃.Et₂O alone had proven to be the best condition for this reaction instead of use of other solvents (Table 2).

Table 2: Screening of solvents.

Entry	Solvents	Isolated Yield (%)		
1	DMSO	30		
2	DMF	26		
3	1,4-Dioxane	62		
4	$BF_3.Et_2O$	68		
5	Acetonitrile	42		
6	THF	15		
7	Toluene	20		

Reaction and conditions: (2-aminophenyl)methanol 9 (1.0 eq), 2-(phenylethynyl)benzonitrile 10 (1.0 eq) BF₃.Et₂O (3.0 eq) at 70 $^{\circ}$ C.

35 With the optimized reaction conditions in hand, we explored the applicability of our reaction. We employed a variety of substituted alcohols and substituted benzonitriles & the results were summarized in **Table 3.** Good yields were observed when the reaction was conducted with (2-aminophenyl)propan-2-ol and (2-aminophenyl)ethanol when compared to (2-aminophenyl)methanol due to the stability of the carbocation.

Table 3: Synthesis of various Isoindoloquinazolinones derivatives.

$$R^3$$
 R^4
 R^5
 R^5
 R^4
 R^5
 R^6

,								
Entry	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	Product	Yield
1	Н	Н	Н	Н	Н	Н	11a	68
2	Н	Н	Н	CH ₃	Н	Н	11b	72
3	Н	Н	Н	Н	Н	Cl	11c	65
4	Н	Н	CH ₃	CH ₃	Н	Н	11d	71
5	Н	Н	CH ₃	Н	Н	Н	11e	69
6	Н	Н	CH ₃	CH ₃	CH ₃	Н	11f	74
7	Н	Н	Н	CH ₃	CH ₃	Н	11g	75
8	Н	Н	Н	CH ₃	CH ₃	OCH ₃	11h	69
9	OCH ₃	OCH ₃	Н	Н	Н	Н	11i	67
10	OCH ₃	OCH ₃	Н	CH ₃	Н	Н	11j	64

70

The Scheme 2 represents a plausible mechanism for the three component reaction leading to the compound 11. The nucleophilic attack of primary amine on nitrile group of 10 yield imidamide intermediate 12, imidamide can attack on alkyne or alcohol leads to the formation of cyclized intermediate either 13 or 15 which on subsequent cyclization will yield the 11.

Scheme 2. Proposed reaction mechanism

In conclusion, we have established a short and efficient methodology for the synthesis of Isoindoloquinazolinone derivatives. The novel synthetic approach involves construction of two new rings *via* sequential C–N bond formation under Lewis Acid condition. This methodology is operationally simple and amenable for scale-up.

Acknowledgments:

10

20 The authors would like to thank Dr. Vilas Dahanukar, Dr. Rama Mohan and the analytical group of CPS-DRL for spectral data.

Notes and references

- Bioactive Heterocyclic Compound Classes: Pharmaceuticals and Agrochemicals (Eds.: C. Lamberth, J. Dinges), Wiley-VCH, New York, 2012.
- (a) Jew, S. S.; Kim, H. J.; Kim, M. G.; Roh, E.Y.; Cho, Y. S.; Kim, J. K.; Cha, K. H.; Lee, K. K.; Han, H. J.; Choi, J. Y.; Lee, H. Bioorg. Med. Chem. Lett. 1996, 6, 845. (b) Lee, J. H.; Lee, J. M.; Kim, J. K.; Ahn, S. K.; Lee, S. J.; Kim, M. Y.; Jew, S. S.; Park, J. G.; Hong, C. Arch. Pharm. Res. 1998, 21, 581.
- (a) Dzierzbicka, K.; Trzonkowski, P.; Sewerynek, P. L.; Mysliwski, A. J. Med. Chem. 2003, 46, 978; (b) Guillaumel, J.; Le'once, S.; Pierre, A.; Renard, P.; Pfeiffer, B.; Arimondo, P. B.; Monneret, C. Eur. J. Med. Chem. 2006, 41, 379; (c) Yilin, R.; Yun Feng, C.; Ting, C.; Chen, A. Y.; Yu, C.; Liu, L. F.; Cheng, C. C. Pharm. Res. 1993, 10, 218
- 4. Friedländer, P.; Roschdestwensky, N. Chem. Ber. 1915, 48, 1841.
- Utkina, N. K.; Fedoreev, S. A.; Tetrahedron Lett. 2007, 48, 4445-4447
 - (a) Ziaee, V.; Jalalizadeh, H.; Iranshahi, M.; Shafiee, A. Iran. J. Chem. Chem. Eng. 2004, 23, 33. (b) Kamal, A.; Ramana, V. K.; Rao, M. V. J. Org. Chem. 2001, 66, 997.
- (a) Harayama, T.; Morikami, Y.; Shigeta, Y.; Abe, H.; Takeuchi, Y. Synlett, 2003, 847-848; (b) Ma, Z.; Hano, Y.; Nomura, T.; Chen, Y. Biorg. Med. Chem. Lett. 2004, 14, 1193-1196; (c) Tseng, M. C.; Chu, Y. W.; Tsai, H. P.; Lin, C. M. Hwang, J.; Chu, Y. H. Org. Lett. 2011, 13, 920-923; (d) Mhaske, S. B.; Argade, N. P. J. Org. Chem.
- 2004, 69, 4563-4566; (e) Chavan, S. P.; Sivappa, R. Tetrahedron,
 2004, 60, 9931-9935; (f) Wagh, M. B.; Shankar, R.; Kumar, U. K.
 S.; Gill, C. H. Synlett, 2011, 84-88; (g) Nagarapu, L.; Gaikwad, H.
 K.; Bantu R. Synlett, 2012, 23, 1775-1778; (h) Tseng, M-C.; Lai, P-Y.; Shi, L.; Li, H-Y.; Tseng, M-J.; Chu, Y-H. Tetrahydron, 2014,

- 70, 2629; (i) Shankar, R.; Wagh, M. B.; Madhubabu, M. V.; Vembu, N.; Kumar, U. K. S. Synlett 2011, 844-848
- Yeulet, S. E.; Mantle, P. G.; Bilton, J. N.; Rzepa, H.S.; Sheppard, R. N.; J. Chem. Soc. Perkin Trans. 1, 1986, 1891-1894
- 9. Li, W.W.; Wang, X.Y.; Zheng, R. L.; Yan, H. X.; Cao, Z. X.; Zhong, L.; Wang, Z. R.; Ji, P.; Yang, L. L.; Wang, L. J.; Xu, Y.; Liu, J. J.; Yang, J.; Zhang, C. H.; Ma, S.; Feng, S.; Sun, Q. Z.; Wei, Y. Q.; Yang, S. Y. *J. Med. Chem.* 2012, **55**, 3852
 - Mitscher, L. A.; Wong, W. C.; De Meulenere, T.; Sulko, J.; Drake, S.; *Heterocycles*, 1981, 15, 1017–1019.
- Bowman, W. R.; Elsegood, M. R. J.; Stein, T. Weaver, G. W. Org. Bomol. Chem. 2007, 5, 103–113.
- (a) Raghavendra R, K.; Ramamohan, M.; Raghunadh, A.; Suresh Babu, M.; Praveen Kumar, S.; Kalita, D.; Laxminarayana, E.; Prasad, B.; Pal. M. RSC Advances, 2015, 5, 61575. (b) Murthy, N, V.; Nikumbh, S, P.; Praveen Kumar, S.; Vaikunta Rao, L.; Raghunadh, A. Tetrahedron Lett. 2015, 56, 5767-5770
- 13. (a) MinQiang, J; Shu, Li, Y.; ACS Catalysis, 2013, 3, 622.
- (a) Yan, H.; Xinying, Z.; Xuesen, F.; Chem. Comm. 2014, 50, 5641.(b) Pu, X.; Li,H.; Colacot, T. J. J.Org. Chem. 2013, 78, 568.

An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazolines derivatives.

 $M.~V.~Madhubabu^a,~R.~Shankar^a,~Satish.s.More^a,~Mandava~V.~Basaveswara~Rao^b,~U.~K.~Syam~Kumar^*{}^a,~and~Ragunadh~Akula*^a$